Key Takeaways; Cannabis Sector

• Organigram to Acquire Aurora Cannabis in C$561 Million Deal, Creating Global Cannabis Powerhouse
• Canopy Growth Posted 22% Revenue Growth as International Cannabis Sales Surged 141% 

Key Takeaways; Psychedelic Sector

• Bright Minds Biosciences Received Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Trial 
• Optimi Health Established Australian Subsidiary to Expand Psychedelic Drug Distribution 
• Compass Pathways Reported Third-Quarter Results as its COMP360 NDA Submission Nears Completion 

Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.

Top Marijuana Companies for the Week

#1: Organigram

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) agreed to acquire Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) in a C$561 million (approximately US$400 million) transaction that will bring together two of Canada’s leading cannabis producers and expand their presence across international markets. Announced on November 3, the agreement will see Organigram acquire all outstanding Aurora shares for C$7.80 per share, offering Aurora shareholders the choice of cash, Organigram shares or a combination of both, subject to certain allocation limits.

The proposed acquisition represents a 93% premium over Aurora’s unaffected closing share price on August 10, 2026, before Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) first disclosed its intention to pursue an unsolicited takeover. It also represents a 21% premium to Curaleaf’s revised hostile offer, which Aurora’s board unanimously rejected. Following a strategic review process, Aurora’s board has recommended that shareholders reject Curaleaf’s bid and support the Organigram transaction.

“This transaction is a defining step in Organigram’s strategy to build a disciplined, global cannabis leader,” said Organigram CEO, James Yamanaka. He added that combining Aurora’s established international medical cannabis platform with Organigram’s Canadian operations and expanding European presence would create a larger, more diversified business positioned to capture growing global demand.

Aurora Executive Chairman and CEO, Miguel Martin, also described the agreement as an opportunity to accelerate the company’s international strategy through stronger commercial operations, expanded product development and research capabilities, and a broader global network. He also highlighted the value and flexibility the transaction offers Aurora shareholders, including the opportunity to participate in the combined company’s future growth.

The acquisition brings together complementary business models. Organigram has a strong position in Canada’s adult-use cannabis market, supported by its established brands and production network, while its acquisition of Germany’s Sanity Group has strengthened its access to Europe’s medical cannabis sector. Aurora, meanwhile, has increasingly concentrated on medical cannabis, with operations and commercial activities across 12 countries, including Germany, Poland and Australia.

The combined company expects to establish a stronger presence in Canada, Europe and Australia, supported by five EU-GMP-certified production and distribution facilities. Its expanded infrastructure is also expected to improve international supply capabilities, product innovation and distribution efficiency.

The acquisition will be supported by Organigram’s strategic shareholder, BT DE Investments Inc., a subsidiary of British American Tobacco p.l.c. (NYSE: BTI). As part of the financing arrangements, BAT has committed to a C$187.5 million private placement, equivalent to £100 million, while ATB Financial has provided committed credit facilities of up to C$210 million. The financing is intended to cover the cash component of the acquisition and associated transaction expenses while maintaining financial flexibility.

Both companies’ boards have unanimously approved the transaction. Completion is expected in January 2027, subject to shareholder and regulatory approvals and a final court order. Special shareholder meetings are anticipated in December 2026.

#2: Canopy Growth

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) reported an increase in revenue for the second quarter of fiscal 2027, supported by stronger cannabis sales across Canada and international markets, particularly Germany and Poland. For the three months ended September 30, 2026, the Canadian cannabis producer generated net revenue of C$81.4 million, up 22% from C$66.7 million in the same period last year.

Cannabis segment revenue increased 30% year over year to C$66.2 million, while revenue from its Storz & Bickel vaporizer business declined 4% to C$15.1 million. Despite the overall revenue growth, consolidated gross margin declined to 29%, compared with 33% in the prior-year quarter. The company also reported a net loss of C$40.7 million, an increase of C$35.7 million year over year, primarily reflecting C$35.8 million in fair value charges related to its Canopy USA assets.

In Canada, medical cannabis revenue rose 18% to C$25.8 million, supported by growth in insured customers and the acquisition of MTL Cannabis. However, the increase was partially offset by the Canadian government’s reduction in Veterans Affairs Canada reimbursement rates for medical cannabis. Adult-use cannabis revenue also increased 17% to C$28.1 million, primarily driven by stronger flower sales following the MTL Cannabis acquisition, although lower opportunistic bulk sales partially offset the gains.

International markets delivered the quarter’s strongest performance, with medical cannabis revenue climbing 141% year over year to C$12.3 million, compared with C$5.1 million in the corresponding period last year. Growth was largely driven by stronger demand in Germany and Poland, reinforcing the company’s international expansion strategy.

Canopy Growth also reported progress in strengthening its European supply capabilities. Its Smiths Falls, Ontario facility received European Union Good Manufacturing Practice (EU GMP) certification, making it Canada’s only certified facility combining softgel manufacturing with primary packaging of softgels, oral liquids and dried cannabis flower. The company’s Kincardine cultivation facility also secured renewed EU GMP certification, supporting its ability to supply regulated European medical cannabis markets.

The company continued expanding its international footprint during the quarter, appointing a country manager in Germany to strengthen its commercial operations and entering the United Kingdom medical cannabis market through distribution partner GROW Group U.K. Ltd. Its Spectrum Therapeutics brand initially introduced four Canadian-grown flower strains in the market. In Australia, Canopy broadened its medical cannabis portfolio through two new product formats, additional oil and softgel formulations, and two new flower products.

Commenting on the results, Chief Executive Officer Luc Mongeau said, “Our international business delivered 141% net revenue growth in the second quarter of fiscal year 2027 driven by strong medical cannabis sales in Germany and Poland.” He also highlighted the company’s UK market entry, expanded Australian portfolio and strengthened EU GMP-certified supply chain as important steps in its international strategy.

Despite continued operating losses, Canopy reported improvements in its adjusted EBITDA performance. Adjusted EBITDA loss narrowed 6% to C$2.9 million from the prior-year period, while free cash outflow declined to C$15.5 million from C$19.2 million. Chief Financial Officer Tom Stewart said the company was “progressing steadily to profitability, quarter after quarter,” adding that its disciplined approach and continued operational improvements put it within reach of achieving positive adjusted EBITDA during fiscal 2027.

Top Psychedelic Companies for Week

#1: Bright Minds

Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) announced that the U.S. FDA had placed a partial clinical hold on its investigational new drug application for BMB-101, targeting developmental and epileptic encephalopathies (DEEs). The company said the decision affects its planned U.S. Phase 2 trial, designated BMB-101-105, which aims to evaluate the safety and efficacy of increasing doses of BMB-101 in patients experiencing seizures associated with DEEs.

According to the company, the FDA’s concerns primarily relate to toxicity findings identified in mice and insufficient pharmacokinetic and juvenile toxicity data to support the proposed enrolment of paediatric patients. Bright Minds stated that the toxicity observed in mice had not been identified in other animal species. Based on its toxicology reports, peer reviews and independent expert assessments, the company believes the findings were incidental and not related to BMB-101.

Bright Minds emphasized that the partial hold is limited to the proposed U.S. Phase 2 DEE trial and does not affect its other ongoing clinical programmes. The company intends to review the FDA’s formal hold letter and modify the study in line with the regulator’s recommendations, with the aim of addressing the outstanding safety concerns and progressing future U.S. clinical development.

The regulatory setback prompted several analysts to reassess their outlook for the company. H.C. Wainwright indicated that the issues appear potentially addressable but expects at least a one-year delay to the U.S. DEE development timeline, subject to the FDA’s requirements. BTIG maintained a Buy rating but significantly reduced its price target from $147 to $37. However, it cautioned that resolving the regulatory concerns could take time, particularly given the high safety requirements associated with developing treatments for children. Meanwhile, Baird lowered its price target from $126 to $107 while maintaining an Outperform rating on the shares.

#2: Optimi Health

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) recently announced the establishment of Optimi Australia Pty Ltd, a wholly owned subsidiary dedicated to strengthening the company’s commercial presence and expanding its distribution network across Australia. The new entity will oversee sales, distribution and relationships with authorized prescribers, clinics and pharmacies throughout the country.

Through Optimi Australia, the company aims to increase access to its finished pharmaceutical products, including naturally derived 5mg psilocybin capsules and 40mg and 60mg MDMA capsules. The products are manufactured at Optimi’s Health Canada-licensed, GMP-compliant facility in Princeton, British Columbia, and supplied to eligible healthcare providers under Australia’s Authorized Prescriber Scheme.

To lead the expansion, Optimi said it had appointed Adrian Jones as Director of Australian Operations. According to the company, Jones brings more than 15 years of pharmaceutical industry experience, most recently serving as Associate Director and Head of Sales and Marketing for Bristol Myers Squibb’s Australian oncology and cardiovascular portfolios. His previous experience also includes positions with Eli Lilly and Hospira.

Optimi CEO, Dane Stevens, highlighted Australia’s importance to the company’s commercial strategy, stating, “Australia is our first commercial market, and we believe demand from authorized prescribers there continues to grow.” He added that establishing a local team under Jones’ leadership would strengthen the company’s ability to support the expanding market. Jones said his immediate priority would be to understand clinicians’ needs and help them deliver treatments as efficiently and effectively as possible.

The establishment of Optimi Australia represents a strategic step in the company’s efforts to expand its international commercial operations and strengthen relationships with healthcare providers. With a dedicated local distribution and business development team, Optimi aims to build on its existing presence in Australia’s regulated psychedelic medicine market while increasing access to its psilocybin- and MDMA-based products.

#3: Compass Pathways

Compass Pathways plc (NASDAQ: CMPS) reported its third-quarter 2026 financial results, highlighting progress toward regulatory submission and commercial launch of its investigational psilocybin treatment, COMP360, for treatment-resistant depression (TRD). The company reported a diluted loss of $0.31 per share, slightly better than analysts’ expectations of a $0.33 loss per share.

The company also reported it is nearing completion of its rolling New Drug Application (NDA) submission to the U.S. FDA, with the final submission expected within the next two weeks. Compass said it is targeting a commercial launch in the first half of 2027, subject to regulatory approval. The company also highlighted the potential for an accelerated review through the National Priority Voucher programme, which could shorten the review period to approximately one to two months.

Compass CEO, Kabir Nath, expressed confidence in the treatment’s commercial potential, stating, “Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm.” He added that the company is preparing to launch the treatment in the first half of 2027 while continuing to advance its post-traumatic stress disorder (PTSD) programme.

According to the company, clinical progress remains a central part of its outlook. Data from its two positive Phase 3 trials, COMP005 and COMP006, have reinforced COMP360’s potential to deliver rapid and sustained improvements in patients with TRD. Notably, 52-week open-label data from COMP005 showed that an additional 25mg dose extended the durability of treatment effects to one year. Compass believes the findings support the potential for a new treatment approach requiring only a few administrations annually.

The company estimates that approximately four million people in the United States live with TRD, representing a significant underserved market. Compass also highlighted that its treatment could fit into more than 8,500 existing treatment centers, supporting its commercial rollout.

Financially, Compass ended September 30, 2026, with $444 million in cash and cash equivalents, compared with $149.6 million at the end of 2025. Management expects its current cash position to fund operating expenses and capital expenditure requirements into 2028, providing financial flexibility beyond the anticipated commercial launch.